Blog

The Petri Dish: CRISPR halts cancer drug work; Apellis investors buoyed by FDA label

the-petri-dish-logo900xx3315-2216-13-0

CRISPR Therapeutics has cut two cancer drug programs, while Apellis investors are breathing sigh of relief after a new FDA label. Plus other life science news you may have missed.

Read More